TITLE:
Development of A Synergistic Novel Therapy against Antimicrobial Resistance Strains of Helicobacter pylori
AUTHORS:
Eucharia Nkiruka Ezeumeh, Chinyelu Nkiru Umeaku, Jude Okpalla, Lilian Chinyere Eleanya, Paul Mmaduabuchukwu Nwafor, Ifeoluwa Bartholomew Olajubu, Oluwafemi Oluwaseun Agboola, Ogechukwu Eucharia Okwueze, Eucharia Amuche Dilibe, Chiderah Louis Dilibe, Joan Chiamaka Okoli
KEYWORDS:
Helicobacter pylori, Probiotics, Lactobacillus rhamnosus Biovar Casei, HpSAg, Columbia-Dent Agar
JOURNAL NAME:
Advances in Infectious Diseases,
Vol.15 No.3,
September
29,
2025
ABSTRACT: Increasing Antimicrobial Resistance (AMR) compromises the treatment of Helicobacter pylori infection globally. This study aimed to use probiotics together with an antibiotic regimen and a proton pump inhibitor to eradicate H. pylori. Stools from positive Helicobacter pylori Stool Antigen (HpSAg), totaling 114 (47.7%) were cultivated on Columbia-based Dent agar (Oxoid) at different times. D Berg’s commercially sourced brand of Lactobacillus rhamnosus/casei probiotic was used. Following biochemical and molecular identification. A per-clinical-factorial-experimental design was employed for the study. Animals, aged 40 weeks old and above were prepared and grouped into six subsets labeled T1 - T6, each defining a particular experimental variable with n = 20. The H. pylori isolates 1 × 108 CFU/ml in normal saline were intraperitoneally administered to the test animals (T2 - T6) over 21 days. Different preparations of probiotics and antibiotics-probiotic therapies were given to the relevant subsets and the outcomes were monitored daily. Fisher’s exact software was used to calculate the error value at 5% (p H. pylori treatment lies in a good Antimicrobial Sensitivity Testing (AST) platform and that only a probiotic-antibiotic regimen can guarantee total eradication (100%) of H. pylori.